<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ddr21709-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 2</label>
 <caption>
  <p>Therapeutics working on multiple targets</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Target</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Specific effect/target molecule(s)</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention(s)</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Status of SARS‐CoV‐2 trial</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Sponsor/collaborators</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">NCT number</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td rowspan="8" align="left" valign="top" colspan="1">Combined intervention</td>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro, interferon receptor (IFNAR)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Lopinavir/ritonavir</p>
     <p>†2 Ribavirin</p>
     <p>†3 Interferon Beta‐1B</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">The University of Hong Kong, Hospital Authority, Hong Kong</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04276688</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro, interferon receptor (IFNAR)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Xiyanping injection</p>
     <p>†2 Lopinavir/ritonavir, alpha‐interferon nebulization</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Not applicable</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Jiangxi Qingfeng Pharmaceutical Co. Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04275388</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">ACE2 and spike binding complex, Endosomal acidification</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Azithromycin</p>
     <p>†2 Chloroquine</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Population Health Research Institute</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04324463</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">ACE2 and spike binding complex, Endosomal acidification</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Azithromycin</p>
     <p>†2 Hydroxychloroquine</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Chronic Obstructive Pulmonary Disease Trial Network, Denmark</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04322396</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">ACE2 and spike binding complex, Endosomal acidification</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Hydroxychloroquine + azithromycin</p>
     <p>†2 Hydroxychloroquine</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Hospital Israelita Albert Einstein, EMS, Hospital do Coracao, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network; Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network, EMS</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04321278, NCT04322123</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Endosomal acidification, RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Hydroxychloroquine</p>
     <p>†2 Remdesivir</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Oslo University Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04321616</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Spike glycoprotein, 3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Carrimycin</p>
     <p>†2 lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Beijing YouAn Hospital, Shenyang Tonglian Group Co., Ltd., Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences, Huangshi Central Hospital, Shenyang Pharmaceutical University, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Harbin Medical University, No. 2 People's Hospital of Fuyang City, First Affiliated Hospital Bengbu Medical College, Renmin Hospital of Wuhan University, The Sixth People's Hospital of Shenyang, Nanyang Central Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04286503</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Spike glycoprotein, 3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Abidol hydrochloride</p>
     <p>†2 Oseltamivir</p>
     <p>†3 Lopinavir/ritonavir</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Tongji Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04255017</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="ddr21709-ntgp-0002">
  <fn id="ddr21709-note-0002">
   <p>
    <italic>Note:</italic> †1, †2, and †3 are different arms of parallel intervention.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
